New combo therapy for lung cancer shows promise in early trial

NCT ID NCT01221077

Completed Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) could help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The study enrolled 88 people who had not received prior chemotherapy. Participants were randomly assigned to receive either the combination or erlotinib plus a placebo. The main goal was to see if the combination delayed cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: erlotinib (Tarceva) and OSI-906
What this could lead to: If successful, this combination could improve how long people with advanced EGFR-mutant lung cancer live without their disease getting worse.
What could go wrong: This is a small, early-phase study (Phase 2) that was completed but the experimental drug OSI-906 was stopped early. Results may not lead to a new standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER NSCLC

Contacts and locations

Locations

Asan Medical Center

Songpa-gu, Seoul, 138736, South Korea
Chonnam National University Hwasun Hospital

Ilsimri, Hwasun-gun, 519809, South Korea
Cleveland Clinic Florida

Weston, Florida, 33331, United States
H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21231, United States
Johns Hopkins Singapore International Medical Centre

Singapore, 308433, Singapore
Juravinski Cancer Centre

Hamilton, Ontario, L8V 5C2, Canada
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Khon Kaen University

Khon Kaen, 40002, Thailand
Korea University Anam Hospital

Seoul, 136705, South Korea
London Regional Cancer Program

London, Ontario, N6A 4L6, Canada
Maharaj Nakorn Chiangmai

Chiang Mai, 50002, Thailand
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10021, United States
National Cancer Institute

Phayathai, Bangkok, 10400, Thailand
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
Oncocare Cancer Center

Singapore, 258499, Singapore
Pamela Youde Nethersole Eastern Hospital

Chai Wan, 852, Hong Kong
Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
Rush University Medical Center

Chicago, Illinois, 60612, United States
Samsung Medical Center

Seoul, 135710, South Korea
Seattle Cancer Care Alliance University of Washington

Seattle, Washington, 98109, United States
Seoul National University Bundang Hospital

Seongnam-si, 463-707, South Korea
Songklanagarind Hospital, Prince of Songkla University

Songkhla, 90110, Thailand
Swedish Cancer Institute

Seattle, Washington, 98104, United States
University of California, San Diego/Moores Cancer Center

La Jolla, California, 92093, United States
University of Tennessee Cancer Institute

Memphis, Tennessee, 31804, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.